The therapeutic role of nutraceuticals targeting the Nrf2/
            <scp>HO</scp>
            ‐1 signaling pathway in liver cancer

Alharbi, Khalid Saad; Almalki, Waleed Hassan; Albratty, Mohammed; Meraya, Abdulkarim M.; Najmi, Asim; Vyas, Govind; Singh, Sachin Kumar; Dua, Kamal; Gupta, Gaurav

doi:10.1111/jfbc.14357

Cited by 20 publications

(3 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In China, LC is prevalent, and most patients are diagnosed in the middle to late stages, losing the opportunity for surgical intervention. With advancements in medical technology, the available treatment options for LC have been rapidly evolving [28,29]. Due to its insidious onset, atypical early symptoms, and diagnostic challenges, most patients with LC are already in the late stage or have distant metastasis at the time of diagnosis, with only about 15% of patients being suitable for surgical resection.…”

Section: Discussionmentioning

confidence: 99%

Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer

Zeng,

Yu,

Chen

et al. 2024

World J Surg Onc

View full text Add to dashboard Cite

Objective The clinical efficacy and safety of sorafenib in patients with advanced liver cancer (ALC) were evaluated based on transarterial chemoembolization (TACE). Methods 92 patients with ALC admitted to our hospital from May 2020 to August 2022 were randomly rolled into a control (Ctrl) group and an observation (Obs) group, with 46 patients in each. Patients in the Ctrl group received TACE treatment, while those in the Obs group received sorafenib molecular targeted therapy (SMTT) on the basis of the treatment strategy in the Ctrl group (400 mg/dose, twice daily, followed by a 4-week follow-up observation). Clinical efficacy, disease control rate (DCR), survival time (ST), immune indicators (CD3+, CD4+, CD4+/CD8+), and adverse reactions (ARs) (including mild fatigue, liver pain, hand-foot syndrome (HFS), diarrhea, and fever) were compared for patients in different groups after different treatments. Results the DCR in the Obs group (90%) was greatly higher to that in the Ctrl group (78%), showing an obvious difference (P < 0.05). The median ST in the Obs group was obviously longer and the median disease progression time (DPT) was shorter, exhibiting great differences with those in the Ctrl group (P < 0.05). Moreover, no great difference was observed in laboratory indicators between patients in various groups (P > 0.05). After treatment, the Obs group exhibited better levels in all indicators. Furthermore, the incidence of ARs in the Obs group was lower and exhibited a sharp difference with that in the Ctrl group (P < 0.05). Conclusion SMTT had demonstrated good efficacy in patients with ALC, improving the DCR, enhancing the immune response of the body, and reducing the incidence of ARs, thereby promoting the disease outcome. Therefore, it was a treatment method worthy of promotion and application.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer

Zeng,

Yu,

Chen

et al. 2024

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Presently, identifying and developing epigenetically based interferences can be a critical anticancer approach [112]. A wide range of studies provide evidence that natural dietary compounds possess the potential for controlling pathways correlated with cancer stem cell pathways with self-renewal, for example, the Hedgehog, Notch, and Wnt/β-catenin pathways [113,114]. Plant-derived compounds like polyphenols also improve negative epigenetic mutations in the cancer cells, hindering carcinogenicity, stopping metastatic progression, and stimulating the tumor cells to chemotherapy or radiotherapy [115].…”

Section: Anticancermentioning

confidence: 99%

Examination of Primary and Secondary Metabolites Associated with a Plant-Based Diet and Their Impact on Human Health

Simsek,

Whitney

2024

Foods

View full text Add to dashboard Cite

The consumption of plant-based diets has become a burgeoning trend, and they are increasingly consumed globally owing to their substantial energy intensity and dietetic advantages. Plants possess numerous bioactive components that have been recognized to exhibit manifold health-promoting assets. Comprehension of the synthesis of these primary and secondary metabolites by plants and their method of action against several chronic illnesses is a significant requirement for understanding their benefits to human health and disease prevention. Furthermore, the association of biologically active complexes with plants, humans, disease, medicine, and the underlying mechanisms is unexplored. Therefore, this review portrays various bioactive components derived from plant sources associated with health-promoting traits and their action mechanisms. This review paper predominantly assembles proposed plant-derived bioactive compounds, postulating valuable evidence aimed at perceiving forthcoming approaches, including the selection of potent bioactive components for formulating functional diets that are effective against several human disorders. This meticulous evidence could perhaps provide the basis for the advanced preemptive and therapeutic potential promoting human health. Hence, delivery opens possibilities for purchasers to approach the lucrative practice of plants as a remedy, produce novel products, and access new marketplaces.

show abstract

“…Carbon monoxide (CO): This signaling molecule stimulates cGMP-mediated vasodilation and suppresses ET-1—thus reducing the severity of hypertension—inhibits the proliferation of vascular smooth muscle cells (reducing need for stenting of cardiac patients); suppresses ventricular fibrillation and ischemia/reperfusion injury; and stabilizes Na + and K + distribution across membranes of cardiovascular cells [ 2 , 143 ].…”

Section: Major Physiologic Effects Of Hmox Product Metabolitesmentioning

confidence: 99%

Evolving Strategies for Use of Phytochemicals in Prevention and Long-Term Management of Cardiovascular Diseases (CVD)

Haines,

Cowan,

Tosaki

2024

IJMS

View full text Add to dashboard Cite

This report describes major pathomechanisms of disease in which the dysregulation of host inflammatory processes is a major factor, with cardiovascular disease (CVD) as a primary model, and reviews strategies for countermeasures based on synergistic interaction between various agents, including drugs and generally regarded as safe (GRAS) natural medical material (NMM), such as Ginkgo biloba, spice phytochemicals, and fruit seed flavonoids. The 15 well-defined CVD classes are explored with particular emphasis on the extent to which oxidative stressors and associated ischemia-reperfusion tissue injury contribute to major symptoms. The four major categories of pharmaceutical agents used for the prevention of and therapy for CVD: statins, beta blockers (β-blockers), blood thinners (anticoagulants), and aspirin, are presented along with their adverse effects. Analyses of major cellular and molecular features of drug- and NMM-mediated cardioprotective processes are provided in the context of their development for human clinical application. Future directions of the evolving research described here will be particularly focused on the characterization and manipulation of calcium- and calcineurin-mediated cascades of signaling from cell surface receptors on cardiovascular and immune cells to the nucleus, with the emergence of both protective and pathological epigenetic features that may be modulated by synergistically-acting combinations of drugs and phytochemicals in which phytochemicals interact with cells to promote signaling that reduces the effective dosage and thus (often) toxicity of drugs.

show abstract

The therapeutic role of nutraceuticals targeting the Nrf2/ HO ‐1 signaling pathway in liver cancer

Cited by 20 publications

References 121 publications

Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer

Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer

Examination of Primary and Secondary Metabolites Associated with a Plant-Based Diet and Their Impact on Human Health

Evolving Strategies for Use of Phytochemicals in Prevention and Long-Term Management of Cardiovascular Diseases (CVD)

Contact Info

Product

Resources

About